Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Teladoc Health, Inc.NYSE: TDOC

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $289.81M rose 47.2% year over year, ahead of the +14.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 47.1% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.

Context

  • Cost of revenue amounted to 30.5% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +47.2% holds above the trailing-twelve-month pace of +14.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$289.81M+47.1% QoQ
Last fiscal yearDec 2025
$771.59M+2.7% YoY
LTMMar 2026
$864.58M+14.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.2%——
1 year+2.7%——
3-year CAGR+1.2%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
771.59M USD
Year-over-year change
+2.7%
4-year CAGR
+4.4%

Cost of Revenue vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.7% is the 4th highest of 11, against a peer median of +8.0%.
  • Cost of revenue amounts to 34.4% of revenue for TDOC, versus a peer median of 48.6%.
TDOC Competitors
Cost of Revenue for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PGNYProgyny, Inc.LTM Jun 2026$988.68M USD+2.5%+16.7%75.4%
TDOCTeladoc Health, Inc.LTM Mar 2026$864.58M USD+14.7%+1.2%34.4%
OMCLOmnicell, Inc.LTM Mar 2026$692.19M USD+7.4%-1.4%56.5%
EVOEvotec SELTM Mar 2026€660.57M EUR-3.0%+6.4%88.6%
AZTAAzenta, Inc.LTM Sep 2026$346.74M USD+8.6%-7.1%55.8%
PHRPhreesia, Inc.LTM Apr 2026$169.46M USD+21.9%+12.1%34.2%
NVCRNovoCure LimitedLTM Mar 2026$167.29M USD+17.8%+13.3%24.8%
SDGRSchrödinger, Inc.LTM Sep 2026$111.68M USD+3.9%+12.3%41.5%
OMDAOmada HealthLTM Mar 2026$95.69M USD+31.6%+24.4%33.8%
IMNMImmunome, Inc.LTM Sep 2026$753K USD-98.5%——
PHVSPharvaris N.V.LTM Sep 2026€106.45K EUR+9.7%——
Peer median (excluding TDOC) —+8.0%+12.2%48.6%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.03B2.41B2.6B2.57B2.53B
Cost of Revenue650.26M743.99M760.03M751.27M771.59M
Gross Profit1.38B1.66B1.84B1.82B1.76B
Gross Margin68.0%69.1%70.8%70.8%69.5%
Research & Development311.88M333.63M348.52M307.27M277.92M
Selling, General & Admin1.11B1.3B1.37B1.35B1.09B
Operating Expenses1.65B15.32B2.09B2.84B2.02B
Depreciation & Amortization207.57M209.93M254.11M240.51M363.12M
EBITDA(31.42M)(7.54M)43.61M31.72M147.3M
EBITDA Margin-1.5%-0.3%1.7%1.2%5.8%
Operating Income(265.63M)(13.65B)(248.55M)(1.02B)(262.96M)
Operating Margin-13.1%-567.3%-9.6%-39.7%-10.4%
Interest Income776K12.67M46.78M57.07M36.77M
Interest Expense81.14M21.94M22.28M23.8M19.71M
Other Income / Expenses(119.03M)(10.13M)28.95M27.23M27.43M
Income Before Tax(384.66M)(13.66B)(219.61M)(993.65M)(235.53M)
Pre-Tax Margin-18.9%-567.7%-8.4%-38.7%-9.3%
Income Tax Expense44.14M(3.81M)760K7.59M(35.21M)
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Net Margin-21.1%-567.5%-8.5%-39.0%-7.9%
EPS (Basic)(2.73)(84.60)(1.36)(5.87)(1.14)
EPS (Diluted)(2.73)(84.60)(1.34)(5.87)(1.14)
Weighted Avg Shares156.94M161.46M162.17M170.56M176.22M
Weighted Avg Shares (Diluted)156.94M161.46M164.58M170.56M176.22M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.